V3381

Vernalis (R&D) Ltd · Phase 2 active Small molecule

At a glance

Generic name	V3381
Also known as	Indantadol
Sponsor	Vernalis (R&D) Ltd
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of the Safety, Tolerability and Efficacy of V3381 in Patients With Diabetic Peripheral Neuropathic Pain (PHASE2)
Phase II Open-Label Pilot Study of V3381 in Chronic Cough (PHASE2)
A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

V3381 CI brief — competitive landscape report
V3381 updates RSS · CI watch RSS
Vernalis (R&D) Ltd portfolio CI